News

Osborne Clarke advises NeRRe Therapeutics on its £20 million Series B2 financing round


Written on 12 July 2021

International law firm Osborne Clarke has advised NeRRe Therapeutics on its £20 million Series B2 financing round. The financing involved a syndicate of leading transatlantic life sciences investors led by new investor Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.

The Osborne Clarke team was led by corporate and venture capital partner Justin Starling and associate director Elizabeth Yell.

NeRRe Therapeutics is a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders.

The proceeds from the financing round will primarily be used to fund the Phase 2 clinical development of orvepitant as a treatment for chronic cough associated with IPF.

Osborne Clarke has a market-leading international venture capital practice and is widely recognized as a leading European law firm for companies operating in the life science and healthcare sector. The Venture Capital team is ranked tier one by The Legal 500 and has experts across London, the Thames Valley and Bristol. It has an outstanding track record advising start-ups, global market leaders, angel investors and institutional VC/growth capital investors on funding rounds, follow-on rounds, venture debt facilities, IPOs, trade sales and buy & build projects.